<DOC>
	<DOCNO>NCT00859157</DOCNO>
	<brief_summary>RATIONALE : New surgery technique may lessen pain breast surgery . It yet know whether tumescent mastectomy standard mastectomy result less pain woman breast cancer . PURPOSE : This clinical trial study pain tumescent mastectomy compare pain standard mastectomy woman stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Pain After Tumescent Mastectomy Standard Mastectomy Women With Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare post-operative pain tumescent v standard mastectomy woman stage I-III breast cancer . Secondary - To compare total time operation incision completion wound closure . - To compare time operation first incision completion skin flap . - To compare total estimate blood loss . - To compare number day Jackson-Pratt drain leave place skin flap wind drainage &gt; 30 mL/24 hour . - To compare incidence wound complication skin necrosis , hematoma , cellulitis , abscess , seroma group . OUTLINE : Patients group accord surgeon provide evaluation treatment recommendation . - Group 1 : Patients undergo standard mastectomy . - Group 2 : Patients undergo tumescent mastectomy . All patient receive standardize post-operative pain management comprise morphine sulfate analgesia equivalent dose hydromorphone hydrochloride 24 hour follow surgery . Patients receive 1-2 oral acetaminophen/oxycodone hydrochloride combination tablet ( comparable amount another narcotic/acetaminophen combination ) every 6 hour need . Pain assess use Short-form McGill Pain Questionnaire ( SF-MPQ ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Postoperative Complications</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Invasive ( ductal lobular ) breast cancer In situ ( ductal ) breast cancer Stage 0III disease Localized disease Candidate curative mastectomy select mastectomy modify radical mastectomy surgical option treatment University California Davis Medical Center Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify WBC ≥ 1,500/mm^3 Platelet count ≥ 90,000/mm^3 PT/PTT ≤ upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test No NYHA cardiac disease class IIIIV Cancer survivor must undergo potentially curative therapy prior malignancy evidence prior malignancy within last 5 year , except effectively treat basal cell squamous cell carcinoma skin , carcinoma situ cervix treat surgery alone , lobular carcinoma situ breast treat surgery alone Body Mass Index ≤ 40 PRIOR CONCURRENT THERAPY : No prior major breast surgery , include breast augmentation reduction surgery No preoperative chemotherapy radiotherapy No concurrent immediate breast reconstruction No concurrent bilateral mastectomy No concurrent narcotic pain medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>perioperative/postoperative complication</keyword>
	<keyword>pain</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>invasive ductal breast carcinoma</keyword>
	<keyword>invasive lobular breast carcinoma</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>